Oncology firm Elekta said that recent research from Princess Margaret Hospital in Toronto showed favorable clinical results from treating early-stage, non-small cell lung cancer with its stereotactic body radiation therapy (SBRT) technology.
Dr. Andrew Hope and colleagues found that 483 operable patients (505 tumors) who declined a thoracotomy and were subsequently treated with image-guided SBRT had overall survival and cancer-specific outcomes similar to those in reported surgical series, according to Elekta. Study results were presented at the annual World Conference on Lung Cancer held earlier this month in Amsterdam.
Hope is a member of the Elekta Lung Research Group, an international collaboration of physicians and physicists that is evaluating clinical outcomes in early-stage, non-small cell lung cancer patients.
